BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the BioXcel Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Bioxcel Therapeutics Inc. (BTAI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 269,687.5 | $1,613,379 | 0.02% | |
| 2. | Millennium Management Israel Englander | 6,560.75 | $39,249 | -19% | 0% |
| 3. | Renaissance Technologies Jim Simons | 4,868.75 | $29,127 | -41% | 0% |
| 4. | Squarepoint Ops LLC Maxime Fortin (Cio) | 4,502.875 | $26,938 | 0% | |
| 5. | 3,712.5 | $22,210 | +115% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.00 | 2,000 | Officer, Director | 2,000 | 2018-03-12 | Filing | |
| $9.34 | 1,554 | Director | 168,320 | 2019-08-23 | Filing | |
| $8.83 | 6,646 | Director | 166,766 | 2019-08-22 | Filing | |
| $8.42 | 1,800 | Director | 160,120 | 2019-08-21 | Filing | |
| $8.89 | 974 | Officer, Director | 9,957 | 2019-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.35 | 165 | Officer | 19,957 | 2024-12-16 | Filing | |
| $0.36 | 2,134 | Large Shareholder, Officer, Director | 59,605 | 2024-12-16 | Filing | |
| $0.36 | 983 | Large Shareholder, Officer, Director | 60,920 | 2024-12-16 | Filing | |
| $0.36 | 372 | Officer | 20,932 | 2024-12-16 | Filing | |
| $0.36 | 205 | Officer | 21,157 | 2024-12-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 79,805.8,125 | $477,558 | 0% | |
| 2. | 74,216.625 | $444,112 | 0% | |
| 3. | 23,788 | $142,309 | 0% | |
| 4. | 19,497.8,125 | $116,667 | 0% | |
| 5. | 12,438.125 | $74,410 | 0% |
News See All
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
Operator: Good morning. And welcome to the BioXcel Therapeutics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions].
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel Therapeutics, Inc.
15 Hot Penny Stocks On the Move
Strong inflation data from January and the Fed's indications that it would take its time before initiating rate cuts threw cold water on investors' hopes of getting rid of uncertainties.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its TRANQUILITY program, provide an update on strategic financing, and review...
5 Best Day Trading Stocks To Buy
HUB Cyber Security Ltd. (NASDAQ:HUBC) provides cyber security solutions.
5 Most Shorted Stocks Right Now
Biomea Fusion, Inc. (NASDAQ:BMEA) is a biotechnology firm seeking to treat cancer and diabetes.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to BioXcel Therapeutics' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the BioXcel Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the BioXcel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
